<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00963872</url>
  </required_header>
  <id_info>
    <org_study_id>2008UC097</org_study_id>
    <secondary_id>MT2008-15</secondary_id>
    <secondary_id>0809M46361</secondary_id>
    <secondary_id>RC1HL099447</secondary_id>
    <nct_id>NCT00963872</nct_id>
  </id_info>
  <brief_title>Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer</brief_title>
  <official_title>MT2008-15: Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematological Malignancies Using a Nonmyeloablative Preparative Regimen and Priming With Complement 3a Fragment (C3a)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving low doses of chemotherapy and total-body irradiation before a donor
      umbilical cord blood transplant helps stop the growth of cancer cells. It may also stop the
      patient's immune system from rejecting the donor's stem cells. The donated stem cells may
      replace the patient's immune cells and help destroy any remaining cancer cells
      (graft-versus-tumor effect).

      PURPOSE: This phase I trial is studying the safety of donor umbilical cord blood transplant
      after fludarabine phosphate, cyclophosphamide, and total-body irradiation in treating
      patients with high-risk hematologic cancer (now closed).

      The Phase II part of this trial is studying whether priming one of two UCB units with C3a
      facilitates engraftment of the treated unit.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE:

        -  Nonmyeloablative preparative regimen: Patients receive fludarabine phosphate IV over 1
           hour on days -6 to -2 and cyclophosphamide IV over 2 hours on day -6. Patients then
           undergo total-body irradiation on day -1. Some patients also receive anti-thymocyte
           globulin IV every 12 hours on days -6, -5, and -4.

        -  Umbilical cord blood (UCB) transplantation: Patients undergo unmanipulated UCB
           transplantation followed by complement 3a fragment primed UCB transplantation on day 0.

      Treatment for graft-vs-host disease prophylaxis is also given.

      After completion of study therapy, patients are followed up periodically for up to 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of efficacy after interim analysis
  </why_stopped>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patients With the Complement 3a (C3a) Unit Predominating</measure>
    <time_frame>Day 180</time_frame>
    <description>Efficacy of the pre-incubation of one of two umbilical cord blood (UCB) units with C3a as part of a unrelated donor double UCB nonmyeloablative transplantation in patients with high-risk hematological malignancies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neutrophil Engraftment</measure>
    <time_frame>Day 42</time_frame>
    <description>Achieving 500 neutrophils/uL by day 42.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor Chimerism in Blood</measure>
    <time_frame>Day 28</time_frame>
    <description>Percentage of donor DNA present in the peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grades II-IV Graft-vs-host Disease</measure>
    <time_frame>Day 0 through Day 100</time_frame>
    <description>Development of graft-versus-host disease through day 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-Relapse Mortality</measure>
    <time_frame>Day 180</time_frame>
    <description>Deaths not due to relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Day 360</time_frame>
    <description>Survival (alive) from transplantation to last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Marrow Chimerism</measure>
    <time_frame>Day 21</time_frame>
    <description>Percentage of donor DNA in the bone marrow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic Graft-Versus-Host Disease</measure>
    <time_frame>Day 360</time_frame>
    <description>Patients who developed chronic graft-versus-host disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse of Disease</measure>
    <time_frame>Day 360</time_frame>
    <description>Patients who developed disease relapse after transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Progression</measure>
    <time_frame>Day 360</time_frame>
    <description>Patients who developed disease progression after transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Recovery</measure>
    <time_frame>Day 180</time_frame>
    <description>Number of patients with &gt;20,000 platelets/uL by day 180</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor Chimerism in Blood</measure>
    <time_frame>Day 60</time_frame>
    <description>Percentage of donor DNA present in the peripheral blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Grades III-IV Graft-vs-host Disease</measure>
    <time_frame>0 to 100 days</time_frame>
    <description>Development of graft-versus-host disease by day 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse Mortality</measure>
    <time_frame>Day 360</time_frame>
    <description>Deaths not due to relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival at Day 720</measure>
    <time_frame>720 days</time_frame>
    <description>Survival (alive) from transplantation to last follow-up at day 720.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse of Disease</measure>
    <time_frame>Day 720</time_frame>
    <description>Patients who developed disease relapse after transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Progression</measure>
    <time_frame>Day 720</time_frame>
    <description>Patients who developed disease progression after transplantation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor Chimerism</measure>
    <time_frame>Day 100</time_frame>
    <description>Percentage of donor DNA in the bone marrow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor Chimerism</measure>
    <time_frame>Day 180</time_frame>
    <description>Percentage of donor DNA in the bone marrow.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor Chimerism</measure>
    <time_frame>Day 360</time_frame>
    <description>Percentage of donor DNA in the bone marrow.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Complement Fragment 3A - Small Cell Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Complement Fragment A - Larger Cell Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>50 mg/kg intravenously (IV) over 2 hours on Day -6.</description>
    <arm_group_label>Complement Fragment 3A - Small Cell Dose</arm_group_label>
    <arm_group_label>Complement Fragment A - Larger Cell Dose</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>40 mg/m^2 over 1 hour on Days -6 through -2.</description>
    <arm_group_label>Complement Fragment 3A - Small Cell Dose</arm_group_label>
    <arm_group_label>Complement Fragment A - Larger Cell Dose</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total body irradiation</intervention_name>
    <description>200 cGy on Day -1</description>
    <arm_group_label>Complement Fragment 3A - Small Cell Dose</arm_group_label>
    <arm_group_label>Complement Fragment A - Larger Cell Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Umbilical cord blood unit with C3a fragment</intervention_name>
    <description>On Day 0, the C3a primed UCB unit will be infused intravenously SECOND, within 30 minutes of the completion of the infusion of the unmanipulated UCB unit, through a central line without in-line filtration in a manner identical to the unmanipulated UCB unit.</description>
    <arm_group_label>Complement Fragment 3A - Small Cell Dose</arm_group_label>
    <arm_group_label>Complement Fragment A - Larger Cell Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Unmanipulated UCB Unit</intervention_name>
    <description>On Day 0, the unmanipulated UCB unit will be infused FIRST through a central line without in-line filtration per institutional guidelines.</description>
    <arm_group_label>Complement Fragment 3A - Small Cell Dose</arm_group_label>
    <arm_group_label>Complement Fragment A - Larger Cell Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Disease Criteria

               -  Acute Leukemias: Must be in remission by morphology (&lt;5% blasts). Note
                  cytogenetic relapse or persistent disease without morphologic relapse is
                  acceptable. Also a small percentage of blasts that is equivocal between marrow
                  regeneration vs. early relapse are acceptable provided there are no associated
                  cytogenetic markers consistent with relapse. (See exclusion criteria for more
                  detailed definition)

               -  Acute myeloid leukemia: high risk CR1 (as evidenced by preceding myelodysplastic
                  syndrome (MDS), high risk cytogenetics such as those associated with MDS or
                  complex karyotype, &gt; 2 cycles to obtain complete remission (CR) or erythroblastic
                  and megakaryocytic); second or greater CR.

               -  Acute lymphoblastic leukemia/lymphoma: high risk CR1 as evidenced by high risk
                  cytogenetics (e.g. t(9;22, t(1;19), t(4;11), other MLL rearrangements) or &gt; 1
                  cycle to obtain CR; second or greater CR.

               -  Burkitt's lymphoma in CR2 or subsequent CR

               -  Natural Killer cell malignancies

               -  Myeloproliferative syndromes/diseases: Chronic myelogenous leukemia (CML) in
                  chronic or accelerated phase but patients must have failed or been intolerant to
                  Imatinib mesylate. EXCLUDED: CML in refractory blast crisis, myelofibrosis,
                  polycythemia vera, and essential thrombocytosis.

               -  Myelodysplastic Syndrome: any subtype including refractory anemia (RA) if severe
                  pancytopenia, high risk complex cytogenetics or International Prognostic Scoring
                  System (IPSS) ≥ intermediate-2 (Int-2). Blasts must be less than 5%. If 5% or
                  more requires therapy pre-transplant to reduce blast count to ≤5%. Patients who
                  receive single agent 5-azacytidine, decitabine or immunomodulating drugs are
                  eligible.

               -  Large-cell lymphoma, Hodgkin's lymphoma and multiple myeloma: patients with
                  chemotherapy sensitive disease that has failed or who are ineligible for an
                  autologous transplant. Patients are eligible for umbilical cord blood (UCB)
                  transplantation if there is no evidence of progressive disease by imaging
                  modalities and/or biopsy. Persistent PET activity, though possibly related to
                  lymphoma, IS NOT an exclusion criterion in the absence of computated tomography
                  (CT) changes in size indicating progression. Large-cell and Hodgkin's lymphoma
                  that is progressive on salvage therapy is NOT eligible. Patients with stable
                  disease are eligible for transplantation if the largest residual nodal mass is &lt;
                  5 cm (approximately). For patients who have responded to preceding therapy, the
                  largest residual mass must represent a 50% reduction and be &lt; 7.5 cm
                  (approximately).

               -  Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone
                  B-cell lymphoma, follicular lymphoma which have progressed after at least two
                  prior therapies. Patients with bulky disease should be considered for debulking
                  chemotherapy before transplant. Patients with refractory disease are eligible,
                  unless has bulky disease and an estimated tumor doubling time of less than one
                  month. Patients with stable disease are eligible for transplantation if the
                  largest residual nodal mass is &lt; 5 cm (approximately). For patients who have
                  responded to preceding therapy, the largest residual mass must represent a 50%
                  reduction and be &lt; 7.5 cm (approximately).

               -  Lymphoplasmacytic lymphoma, mantle-cell lymphoma, prolymphocytic leukemia are
                  eligible after initial therapy if chemotherapy sensitive. Mantle-cell lymphoma
                  that is progressive on salvage therapy is NOT eligible. Patients with stable
                  disease are eligible for transplantation if the largest residual nodal mass is &lt;
                  5 cm (approximately). For patients who have responded to preceding therapy, the
                  largest residual mass must represent a 50% reduction and be &lt; 7.5 cm
                  (approximately).

          -  Umbilical Cord Blood Graft Selection - Two UCB units will be compose the graft, and
             each unit must be a 4-6 HLA-A, B, DRB1 antigen match to each other, as well as a 4-6
             antigen match to the recipient. The combined cryopreserved nucleated cell dose of the
             2 units must be ≥ 3 X 10^7/kg with each unit having a minimum cell dose of 1.5 X
             10^7/kg. UCB units will be selected according to a common umbilical cord blood graft
             selection algorithm

          -  Performance Status - adequate performance status defined as Karnofsky score ≥ 60

          -  Age 18 to 70 years of age; patients ≥ 70 but ≤ 75 years are eligible if the
             co-morbidity score is ≤ 2

          -  Organ Function

               -  Cardiac: Left ventricular ejection fraction &gt; 35%; absence of decompensated
                  congestive heart failure; absence of uncontrolled arrhythmia

               -  Pulmonary: DLCO &gt; 30% of predicted; absence of O2 requirements

               -  Hepatic: ALT, AST, alkaline phosphatase and bilirubin &lt; 5 x upper limit of normal

               -  Renal: Creatinine ≤ 2 mg/dl (patients with a creatinine &gt; 1.2 or history of renal
                  dysfunction must have calculated glomerular filtration rate (GFR) &gt; 40
                  mL/min/1.73m2)

               -  If recent mold infection e.g. Aspergillus - must have minimum of 30 days of
                  appropriate treatment before transplant and infection controlled and be cleared
                  by Infectious Disease.

               -  The following conditions must be met:

                    -  If prior myeloablative autologous transplant, must be &gt; 3 months but ≤ 12
                       months from transplant OR have received at least 2 cycles of multi-agent or
                       highly immunosuppressive chemotherapy (i.e. induction for acute leukemia)
                       within the 3 months preceding this study. OR

                    -  If neither prior myeloablative autologous transplant ≤ 12 months from
                       transplant nor have received at least 2 cycles of multi-agent or highly
                       immunosuppressive chemotherapy (i.e. induction for acute leukemia) within
                       the 3 months preceding this study, patients are eligible as long as they
                       receive equine anti-thymocyte globulin as part of the conditioning regimen.

        Exclusion Criteria:

          -  Patients who have an available, medically suitable, 5-6/6 HLA-A, B, DRB1 matched
             sibling donor

          -  Patients who are eligible for autologous transplantation

          -  Prior allogeneic transplant

          -  Acquired or inherited bone marrow failure syndromes such as aplastic anemia and
             Fanconi anemia

          -  Pregnant or breast feeding

          -  Evidence of HIV infection or known HIV positive serology

          -  Current uncontrolled serious infection

          -  Active central nervous system malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio G. Brunstein, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Minnesota Medical Center - Fairview</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2009</study_first_submitted>
  <study_first_submitted_qc>August 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 24, 2009</study_first_posted>
  <results_first_submitted>April 22, 2015</results_first_submitted>
  <results_first_submitted_qc>October 13, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 10, 2015</results_first_posted>
  <last_update_submitted>December 3, 2017</last_update_submitted>
  <last_update_submitted_qc>December 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Complement System Proteins</mesh_term>
    <mesh_term>Complement C3a</mesh_term>
    <mesh_term>Complement C3</mesh_term>
    <mesh_term>Vidarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited at the time of clinic visit or hospitalization. Patients that were considered for umbilical cord transplant were approached with the study.</recruitment_details>
      <pre_assignment_details>Subjects that were eligible for umbilical cord transplant were considered for the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Complement Fragment 3A - Small Cell Dose</title>
          <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.</description>
        </group>
        <group group_id="P2">
          <title>Complement Fragment A - Larger Cell Dose</title>
          <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Two patients were unevaluable because 1 bag broke so only 1 cord was available. One subject never received the C3a.</population>
      <group_list>
        <group group_id="B1">
          <title>Complement Fragment 3A - Small Cell Dose</title>
          <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.</description>
        </group>
        <group group_id="B2">
          <title>Complement Fragment A - Larger Cell Dose</title>
          <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="31"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="13.0"/>
                    <measurement group_id="B2" value="50" spread="15.7"/>
                    <measurement group_id="B3" value="54" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Patients With the Complement 3a (C3a) Unit Predominating</title>
        <description>Efficacy of the pre-incubation of one of two umbilical cord blood (UCB) units with C3a as part of a unrelated donor double UCB nonmyeloablative transplantation in patients with high-risk hematological malignancies.</description>
        <time_frame>Day 180</time_frame>
        <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
        <group_list>
          <group group_id="O1">
            <title>Complement Fragment 3A - Small Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.</description>
          </group>
          <group group_id="O2">
            <title>Complement Fragment A - Larger Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients With the Complement 3a (C3a) Unit Predominating</title>
          <description>Efficacy of the pre-incubation of one of two umbilical cord blood (UCB) units with C3a as part of a unrelated donor double UCB nonmyeloablative transplantation in patients with high-risk hematological malignancies.</description>
          <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Neutrophil Engraftment</title>
        <description>Achieving 500 neutrophils/uL by day 42.</description>
        <time_frame>Day 42</time_frame>
        <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
        <group_list>
          <group group_id="O1">
            <title>Complement Fragment 3A - Small Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.</description>
          </group>
          <group group_id="O2">
            <title>Complement Fragment A - Larger Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Neutrophil Engraftment</title>
          <description>Achieving 500 neutrophils/uL by day 42.</description>
          <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Donor Chimerism in Blood</title>
        <description>Percentage of donor DNA present in the peripheral blood</description>
        <time_frame>Day 28</time_frame>
        <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
        <group_list>
          <group group_id="O1">
            <title>Complement Fragment 3A - Small Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.</description>
          </group>
          <group group_id="O2">
            <title>Complement Fragment A - Larger Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Donor Chimerism in Blood</title>
          <description>Percentage of donor DNA present in the peripheral blood</description>
          <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
          <units>percentage of donor DNA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92" spread="15"/>
                    <measurement group_id="O2" value="96" spread="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Grades II-IV Graft-vs-host Disease</title>
        <description>Development of graft-versus-host disease through day 100.</description>
        <time_frame>Day 0 through Day 100</time_frame>
        <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
        <group_list>
          <group group_id="O1">
            <title>Complement Fragment 3A - Small Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.</description>
          </group>
          <group group_id="O2">
            <title>Complement Fragment A - Larger Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Grades II-IV Graft-vs-host Disease</title>
          <description>Development of graft-versus-host disease through day 100.</description>
          <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-Relapse Mortality</title>
        <description>Deaths not due to relapse.</description>
        <time_frame>Day 180</time_frame>
        <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
        <group_list>
          <group group_id="O1">
            <title>Complement Fragment 3A - Small Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.</description>
          </group>
          <group group_id="O2">
            <title>Complement Fragment A - Larger Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Non-Relapse Mortality</title>
          <description>Deaths not due to relapse.</description>
          <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Survival (alive) from transplantation to last follow-up.</description>
        <time_frame>Day 360</time_frame>
        <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
        <group_list>
          <group group_id="O1">
            <title>Complement Fragment 3A - Small Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.</description>
          </group>
          <group group_id="O2">
            <title>Complement Fragment A - Larger Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Survival (alive) from transplantation to last follow-up.</description>
          <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Marrow Chimerism</title>
        <description>Percentage of donor DNA in the bone marrow.</description>
        <time_frame>Day 21</time_frame>
        <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
        <group_list>
          <group group_id="O1">
            <title>Complement Fragment 3A - Small Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.</description>
          </group>
          <group group_id="O2">
            <title>Complement Fragment A - Larger Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Marrow Chimerism</title>
          <description>Percentage of donor DNA in the bone marrow.</description>
          <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
          <units>percentage of donor DNA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84" spread="25"/>
                    <measurement group_id="O2" value="89" spread="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Chronic Graft-Versus-Host Disease</title>
        <description>Patients who developed chronic graft-versus-host disease.</description>
        <time_frame>Day 360</time_frame>
        <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
        <group_list>
          <group group_id="O1">
            <title>Complement Fragment 3A - Small Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.</description>
          </group>
          <group group_id="O2">
            <title>Complement Fragment A - Larger Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Chronic Graft-Versus-Host Disease</title>
          <description>Patients who developed chronic graft-versus-host disease.</description>
          <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relapse of Disease</title>
        <description>Patients who developed disease relapse after transplantation.</description>
        <time_frame>Day 360</time_frame>
        <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
        <group_list>
          <group group_id="O1">
            <title>Complement Fragment 3A - Small Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.</description>
          </group>
          <group group_id="O2">
            <title>Complement Fragment A - Larger Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse of Disease</title>
          <description>Patients who developed disease relapse after transplantation.</description>
          <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Progression</title>
        <description>Patients who developed disease progression after transplantation.</description>
        <time_frame>Day 360</time_frame>
        <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
        <group_list>
          <group group_id="O1">
            <title>Complement Fragment 3A - Small Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.</description>
          </group>
          <group group_id="O2">
            <title>Complement Fragment A - Larger Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Progression</title>
          <description>Patients who developed disease progression after transplantation.</description>
          <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Recovery</title>
        <description>Number of patients with &gt;20,000 platelets/uL by day 180</description>
        <time_frame>Day 180</time_frame>
        <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
        <group_list>
          <group group_id="O1">
            <title>Complement Fragment 3A - Small Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.</description>
          </group>
          <group group_id="O2">
            <title>Complement Fragment A - Larger Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Recovery</title>
          <description>Number of patients with &gt;20,000 platelets/uL by day 180</description>
          <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Donor Chimerism in Blood</title>
        <description>Percentage of donor DNA present in the peripheral blood</description>
        <time_frame>Day 60</time_frame>
        <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
        <group_list>
          <group group_id="O1">
            <title>Complement Fragment 3A - Small Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.</description>
          </group>
          <group group_id="O2">
            <title>Complement Fragment A - Larger Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Donor Chimerism in Blood</title>
          <description>Percentage of donor DNA present in the peripheral blood</description>
          <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
          <units>percentage of donor DNA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91" spread="23"/>
                    <measurement group_id="O2" value="97" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Grades III-IV Graft-vs-host Disease</title>
        <description>Development of graft-versus-host disease by day 100.</description>
        <time_frame>0 to 100 days</time_frame>
        <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
        <group_list>
          <group group_id="O1">
            <title>Complement Fragment 3A - Small Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.</description>
          </group>
          <group group_id="O2">
            <title>Complement Fragment A - Larger Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Grades III-IV Graft-vs-host Disease</title>
          <description>Development of graft-versus-host disease by day 100.</description>
          <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Non-relapse Mortality</title>
        <description>Deaths not due to relapse.</description>
        <time_frame>Day 360</time_frame>
        <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
        <group_list>
          <group group_id="O1">
            <title>Complement Fragment 3A - Small Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.</description>
          </group>
          <group group_id="O2">
            <title>Complement Fragment A - Larger Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Non-relapse Mortality</title>
          <description>Deaths not due to relapse.</description>
          <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival at Day 720</title>
        <description>Survival (alive) from transplantation to last follow-up at day 720.</description>
        <time_frame>720 days</time_frame>
        <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
        <group_list>
          <group group_id="O1">
            <title>Complement Fragment 3A - Small Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.</description>
          </group>
          <group group_id="O2">
            <title>Complement Fragment A - Larger Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival at Day 720</title>
          <description>Survival (alive) from transplantation to last follow-up at day 720.</description>
          <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relapse of Disease</title>
        <description>Patients who developed disease relapse after transplantation.</description>
        <time_frame>Day 720</time_frame>
        <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
        <group_list>
          <group group_id="O1">
            <title>Complement Fragment 3A - Small Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.</description>
          </group>
          <group group_id="O2">
            <title>Complement Fragment A - Larger Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Relapse of Disease</title>
          <description>Patients who developed disease relapse after transplantation.</description>
          <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Progression</title>
        <description>Patients who developed disease progression after transplantation.</description>
        <time_frame>Day 720</time_frame>
        <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
        <group_list>
          <group group_id="O1">
            <title>Complement Fragment 3A - Small Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.</description>
          </group>
          <group group_id="O2">
            <title>Complement Fragment A - Larger Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Progression</title>
          <description>Patients who developed disease progression after transplantation.</description>
          <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Donor Chimerism</title>
        <description>Percentage of donor DNA in the bone marrow.</description>
        <time_frame>Day 100</time_frame>
        <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
        <group_list>
          <group group_id="O1">
            <title>Complement Fragment 3A - Small Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.</description>
          </group>
          <group group_id="O2">
            <title>Complement Fragment A - Larger Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Donor Chimerism</title>
          <description>Percentage of donor DNA in the bone marrow.</description>
          <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
          <units>percentage of donor DNA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" spread="22"/>
                    <measurement group_id="O2" value="94" spread="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Donor Chimerism</title>
        <description>Percentage of donor DNA in the bone marrow.</description>
        <time_frame>Day 180</time_frame>
        <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
        <group_list>
          <group group_id="O1">
            <title>Complement Fragment 3A - Small Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.</description>
          </group>
          <group group_id="O2">
            <title>Complement Fragment A - Larger Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Donor Chimerism</title>
          <description>Percentage of donor DNA in the bone marrow.</description>
          <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
          <units>percentage of donor DNA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99" spread="3"/>
                    <measurement group_id="O2" value="100" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Donor Chimerism</title>
        <description>Percentage of donor DNA in the bone marrow.</description>
        <time_frame>Day 360</time_frame>
        <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
        <group_list>
          <group group_id="O1">
            <title>Complement Fragment 3A - Small Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.</description>
          </group>
          <group group_id="O2">
            <title>Complement Fragment A - Larger Cell Dose</title>
            <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Donor Chimerism</title>
          <description>Percentage of donor DNA in the bone marrow.</description>
          <population>Two patients were unevaluable - one, because 1 bag of cord blood broke leaving only 1 cord available, and one subject never received the C3a.</population>
          <units>percentage of donor DNA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93" spread="19"/>
                    <measurement group_id="O2" value="100" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>100 days after umbilical cord blood transplant</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Complement Fragment 3A - Small Cell Dose</title>
          <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the smaller cell dose following preparation regimen and radiation.</description>
        </group>
        <group group_id="E2">
          <title>Complement Fragment A - Larger Cell Dose</title>
          <description>Patients who received complement fragment 3a (C3a) priming of the UCB unit with the larger cell dose.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE version 4">Blood and lymphatic disorders- Other</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title vocab="CTCAE version 4">Leukocytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <description>Death due to disease</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Catheter related infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Renal and urinary disorders- Other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pleuritic plan</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="24" subjects_affected="24" subjects_at_risk="24"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurologic disorder</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Claudio Brunstein</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612-625-3918</phone>
      <email>bruns072@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

